Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Veru from a “buy” rating to a “hold” rating in a research report on Tuesday, February 18th. ValuEngine upgraded shares of Veru from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $6.00 price target (up from $4.50) on shares of Veru in a research report on Tuesday, January 21st. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $6.17.
NASDAQ:VERU opened at $4.25 on Tuesday. The company’s 50-day moving average price is $4.08 and its 200-day moving average price is $2.67. The company has a current ratio of 0.99, a quick ratio of 0.72 and a debt-to-equity ratio of 0.06. The company has a market cap of $277.72 million, a P/E ratio of -21.25 and a beta of 0.50. Veru has a twelve month low of $1.18 and a twelve month high of $4.74.
Veru (NASDAQ:VERU) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.05) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.03). Veru had a negative return on equity of 40.45% and a negative net margin of 36.58%. The business had revenue of $10.58 million during the quarter, compared to analysts’ expectations of $9.30 million. On average, analysts expect that Veru will post -0.21 earnings per share for the current year.
In other news, CEO Mitchell Shuster Steiner sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $2.27, for a total transaction of $56,750.00. Insiders have acquired a total of 11,000 shares of company stock valued at $39,890 in the last quarter. 26.10% of the stock is currently owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its position in Veru by 65.4% in the second quarter. BlackRock Inc. now owns 228,934 shares of the company’s stock valued at $487,000 after acquiring an additional 90,530 shares in the last quarter. Tower Research Capital LLC TRC acquired a new position in shares of Veru during the third quarter valued at $25,000. Squarepoint Ops LLC acquired a new position in Veru in the third quarter valued at about $39,000. Wedge Capital Management L L P NC lifted its stake in Veru by 59.2% in the fourth quarter. Wedge Capital Management L L P NC now owns 294,207 shares of the company’s stock valued at $986,000 after buying an additional 109,370 shares during the period. Finally, Alpine Global Management LLC acquired a new position in Veru in the fourth quarter valued at about $80,000. Hedge funds and other institutional investors own 13.55% of the company’s stock.
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Recommended Story: How can investors find ex-dividend dates?
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.